Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

Pharmacology
Hans PrenenErnst de Bruijn

Abstract

Imatinib and AMN107 are protein tyrosine kinase inhibitors which reduce KIT autophosphorylation with similar potency. This report describes the cellular uptake of these compounds in two human gastrointestinal stromal tumor (GIST)-derived cell lines (GIST882 and GIST GDG1), which both express constitutively activated KIT. In GIST882 and GIST GDG1 cell lines, HPLC analysis revealed AMN107 intracellular concentrations to be 7- and 10-fold greater than those of imatinib. These data indicate either increased cellular uptake or decreased cellular efflux of AMN107 when compared to imatinib in GIST cell lines. The finding suggests that AMN107 might be less susceptible to transport-driven imatinib resistance. The stable and increased exposure of GIST cells to a highly active AMN107 agent could be important in the treatment of imatinib-resistant GIST patients in whom resistance has developed as a result of changes in cellular transport mechanisms for which AMN107 is not a substrate.

References

Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Nov 14, 2001·Lancet·A T van OosteromUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Jul 3, 2002·Human Pathology·Christopher D M FletcherSharon W Weiss
Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
Jan 11, 2003·Science·Michael C HeinrichJonathan A Fletcher
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Akinobu HamadaHideyuki Saito
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin

❮ Previous
Next ❯

Citations

Dec 1, 2010·Cancer Chemotherapy and Pharmacology·Mrinal M Gounder, Robert G Maki
Nov 10, 2011·Investigational New Drugs·Jin Hyun ChoJeeyun Lee
Sep 10, 2008·Current Oncology Reports·Peter Reichardt
Feb 15, 2007·Proceedings of the National Academy of Sciences of the United States of America·Varvara TrachanaCarlos Martínez-A
Mar 21, 2012·Anti-cancer Drugs·Maria Abbondanza PantaleoUNKNOWN GIST Study Group, University of Bologna, Bologna, Italy
Sep 3, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George D DemetriPeter Reichardt
Sep 4, 2012·Therapeutic Advances in Medical Oncology·Damien Kee, John R Zalcberg
Jan 5, 2011·Journal of Experimental & Clinical Cancer Research : CR·Maria Abbondanza PantaleoGuido Biasco
Oct 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura E Macconaill, Levi A Garraway
Nov 20, 2009·PloS One·Laura E MacConaillLevi A Garraway
Nov 19, 2009·Drug Design, Development and Therapy·Ronan SwordsFrancis Giles
Jun 11, 2011·Biomarkers in Medicine·Saed Ziaaldin SamsamshariatNizal Sarrafzadegan
Feb 19, 2013·Future Oncology·Rajeev RajendraRobin L Jones
Feb 24, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtP Rutkowski
Mar 27, 2012·Expert Opinion on Therapeutic Targets·Francesco Giuliani, Giuseppe Colucci
Jul 10, 2013·Expert Opinion on Pharmacotherapy·Tatsuo KandaToshirou Nishida
Oct 10, 2007·Expert Opinion on Investigational Drugs·Kamalesh K Sankhala, Kyriakos P Papadopoulos
Oct 27, 2006·Expert Opinion on Emerging Drugs·Monica BocchiaFrancesco Lauria
Apr 17, 2012·Expert Opinion on Investigational Drugs·An Tran, Hussein A Tawbi
Jun 23, 2015·Expert Opinion on Investigational Drugs·Hani J AlturkmaniAndrew K Godwin
Apr 1, 2011·Seminars in Oncology·Jean-Yves Blay, Margaret von Mehren
Nov 17, 2009·Cancer Treatment Reviews·Maria Abbondanza PantaleoGuido Biasco
Dec 30, 2006·Seminars in Diagnostic Pathology·José Antonio López-GuerreroAntonio Llombart-Bosch
Nov 10, 2011·Journal of Surgical Oncology·Edward J Kim, Mark M Zalupski
Sep 12, 2006·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Gunther GuetensErnst A de Bruijn
Apr 14, 2010·Biochemical Pharmacology·Stefan Duensing, Anette Duensing
Jun 17, 2015·Nature Reviews. Clinical Oncology·Maria A Pantaleo, Guido Biasco
Apr 18, 2015·The Lancet Oncology·Xavier Garcia del Muro
Nov 15, 2014·Future Oncology·Maristella SaponaraGuido Biasco
May 3, 2014·Therapeutic Advances in Medical Oncology·César Serrano, Suzanne George
Nov 20, 2009·Clinical Pharmacology and Therapeutics·C TanakaH Schran
Aug 23, 2006·Laboratory Investigation; a Journal of Technical Methods and Pathology·Brian P Rubin, Anette Duensing
Aug 6, 2008·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·S Grether-BeckJ Krutmann
Nov 18, 2011·Seminars in Immunopathology·Bonggoo Park, George Y Liu
Aug 22, 2009·Wiener medizinische Wochenschrift·Ferdinand Ploner, Wolfgang Eisterer
May 6, 2010·Molecular Cancer Therapeutics·Carleen CullinaneGrant A McArthur

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M MontemurroSerge Leyvraz
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Michael C HeinrichJonathan Fletcher
© 2021 Meta ULC. All rights reserved